Compare VFC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VFC | CYTK |
|---|---|---|
| Founded | 1899 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | VFC | CYTK |
|---|---|---|
| Price | $19.46 | $63.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | $16.13 | ★ $77.87 |
| AVG Volume (30 Days) | ★ 6.0M | 1.8M |
| Earning Date | 01-28-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $9,541,055,000.00 | $87,211,000.00 |
| Revenue This Year | $0.66 | $361.33 |
| Revenue Next Year | $0.96 | $65.14 |
| P/E Ratio | $84.84 | ★ N/A |
| Revenue Growth | N/A | ★ 2609.26 |
| 52 Week Low | $9.41 | $29.31 |
| 52 Week High | $29.02 | $69.33 |
| Indicator | VFC | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 67.78 | 49.38 |
| Support Level | $18.06 | $59.56 |
| Resistance Level | $20.30 | $67.26 |
| Average True Range (ATR) | 0.81 | 2.35 |
| MACD | 0.15 | -0.66 |
| Stochastic Oscillator | 78.63 | 36.03 |
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.